Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew G Renehan

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
British Journal of Cancer|November 25, 2020
Cancer prevention through weight control-where are we in 2020?Annie S Anderson, Andrew G Renehan, John M Saxton, et al.
BMJ Open|March 30, 2023
Protocol for the CoNoR Study: A prospective multi-step study of the potential added benefit of two novel assessment tools in colorectal liver metastases technical resectability decision-makingKat L Parmar, Derek O'Reilly, Juan Valle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancerAlison Backen, Andrew G Renehan, Andrew R Clamp, et al.
British Journal of Cancer|January 15, 2020
Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014)Hema Sekhar, Lee Malcomson, Rohit Kochhar, et al.
Clinical Colorectal Cancer|February 15, 2015
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal CancerMatthew G Krebs, Andrew G Renehan, Alison Backen, et al.
BMJ Open|September 24, 2020
Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF StudyKat L Parmar, Derek O'Reilly, Juan W Valle, et al.
The Lancet. Oncology|December 4, 2014
Global burden of cancer attributable to high body-mass index in 2012: a population-based studyMelina Arnold, Nirmala Pandeya, Graham Byrnes, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 21, 2024
The risk of developing pseudomyxoma peritonei from a non-perforated low grade appendiceal mucinous neoplasm found at appendicectomyChamila Lakmal, Bipasha Chakrabarty, Christine Tan, et al.
British Journal of Cancer|November 25, 2020
Cancer survivorship, excess body fatness and weight-loss intervention-where are we in 2020?Annie S Anderson, Richard M Martin, Andrew G Renehan, et al.
Eclinicalmedicine|December 25, 2024
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome setRobert Samuel, Stephen R Knight, Richard Adams, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
British Journal of Cancer|November 25, 2020
Cancer prevention through weight control-where are we in 2020?Annie S Anderson, Andrew G Renehan, John M Saxton, et al.
BMJ Open|March 30, 2023
Protocol for the CoNoR Study: A prospective multi-step study of the potential added benefit of two novel assessment tools in colorectal liver metastases technical resectability decision-makingKat L Parmar, Derek O'Reilly, Juan Valle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancerAlison Backen, Andrew G Renehan, Andrew R Clamp, et al.
British Journal of Cancer|January 15, 2020
Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014)Hema Sekhar, Lee Malcomson, Rohit Kochhar, et al.
Clinical Colorectal Cancer|February 15, 2015
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal CancerMatthew G Krebs, Andrew G Renehan, Alison Backen, et al.
BMJ Open|September 24, 2020
Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF StudyKat L Parmar, Derek O'Reilly, Juan W Valle, et al.
The Lancet. Oncology|December 4, 2014
Global burden of cancer attributable to high body-mass index in 2012: a population-based studyMelina Arnold, Nirmala Pandeya, Graham Byrnes, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 21, 2024
The risk of developing pseudomyxoma peritonei from a non-perforated low grade appendiceal mucinous neoplasm found at appendicectomyChamila Lakmal, Bipasha Chakrabarty, Christine Tan, et al.
British Journal of Cancer|November 25, 2020
Cancer survivorship, excess body fatness and weight-loss intervention-where are we in 2020?Annie S Anderson, Richard M Martin, Andrew G Renehan, et al.
Eclinicalmedicine|December 25, 2024
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome setRobert Samuel, Stephen R Knight, Richard Adams, et al.
Pageof 12